Stockholm, Sweden, November 17, 2025 - Alex Therapeutics, a Stockholm-based digital health manufacturer, and Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, have launched the companion app Levilog to support patients in the treatment of Parkinson’s disease.

The app is a Class 1 CE-marked medical device that provides digital treatment support for patients prescribed the Parkinson’s medication Flexilev®. It works as a three-part solution in combination with the next-generation dose dispenser OraFID®, delivering a seamless and individualized approach to medication management.

Enabling Patients Through Digital Support

The companion app provides medication management features, including scheduled reminders, dosage tracking, personal insights, and refill notifications, to help patients adhere to their treatment regimens. As people living with Parkinson’s disease commonly face daily challenges—such as fluctuating motor function and cognitive changes—the app aims to make daily treatment simpler and more reliable.

“Following a successful development phase with patients living with Parkinson’s, we’re thrilled to now bring this digital companion to the community,” says Kathrine Gamborg Andreassen, CEO of Navamedic. “Our collaboration with Alex Therapeutics reinforces our mission to make advanced treatments more accessible and easier to manage, empowering patients to live with greater confidence and control.”

John Drakenberg, CEO and Founder of Alex Therapeutics, adds:
“We’re proud to see this partnership come to life to make a real-world impact. By combining our expertise in digital health with Navamedic’s strong patient-centric focus, we’re enabling better treatment outcomes and helping to improve the everyday lives of people living with Parkinson’s.”

Now Available in the Nordics

The companion app is now available at the App Store and Google Play in the Nordics. Further European expansion is planned in collaboration with Orion Pharma, a globally operating Nordic pharmaceutical company and Navamedic partner. The launch marks a significant step in integrating digital health solutions into traditional pharmaceutical care pathways, supporting adherence, engagement, and improved health outcomes.

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). Sensidose is a fully owned subsidiary of Navamedic. For more information, visit: www.navamedic.com

About Orion

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.

About Alex Therapeutics

Alex Therapeutics is a digital health company based in Stockholm that partners with pharmaceutical companies to support people with treatment and disease-related mental health challenges through clinically validated companion apps. Alex Therapeutics specializes in oncology and rare diseases, which typically entail complex treatment regimes and psychological distress. For more information, visit: www.alextherapeutics.com

Media Contacts

Navamedic

Kathrine Gamborg Andreassen, CEO

kathrine@navamedic.com 

‍

Alex Therapeutics

Meera Montan, Director of Growth

meera.montan@alextherapeutics.com

‍